Hydrogène de France Announces the World's First Plant for Mass Production of High-Powered Fuel Cells (Over 1 MW)
10.12.2019 23:00:00 EET | Business Wire | Press release
Hydrogène de France (HDF) becomes a French industrial company by launching its high-powered fuel cell production plant in Bordeaux. This plant, with an annual production capacity of 50 MW, will be the first in the world to mass produce high-powered PACs (greater than 1 MW) using PEM (Proton Exchange Membrane) technology. The industrialization and standardization of these systems reduces their cost and improves significantly their reliability and maintenance.
This plant will produce under the brand name "HDF Industry". It will integrate the Fuel Cell stacks of Canadian company Ballard, which today has the most widely deployed technology in the world. This exclusive worldwide agreement allows HDF to offer high-powered FCs whose performance and prices are adapted to the energy market.
A worldwide ambition
HDF intends to play a pioneering role in the emerging hydrogen market. Hydrogen, considered by both industrialists and governments as one of the solutions for the energy transition, is developing in multiple directions, including mobility as well as stationary applications.
HDF's vision is based on the development of hydrogen as a fuel and a vehicle for storing electricity. Renewable energies have conquered a place in the world of energy by overcoming the challenge of competitiveness. HDF believes that the time has come to take on the next challenge, that of intermittency.
An industrial reality
HDF started its industrial program 3 years ago consulting the world's leading fuel cell companies. Ballard was selected as being the ideal partner, as they have demonstrated their experience, industrial capacity and stack lifetime. HDF's industrial plan has been developed with the ClearGen and CEOG projects and with the expertise of its employees.
The HDF Industry plant will have a production capacity of 50MW of Fuel Cell per year within 5 years.
Benefiting from Ballard's know-how and HDF's unique experience in industrial hydrogen projects, this French multimegawatt fuel cell plant has a sizeable lead in the market.
Damien Havard, President and Founder of HDF:
We are particularly pleased with this cooperation with Ballard. HDF industrializes reliable FCs at a price adapted to the market. The standardization of this strategic brick will allow the production of non-polluting and competitive electricity on a large scale. HDF provides the industrial solution that was missing to develop the massive storage of renewable energy. Our market is huge: this is the end of the intermittency of renewable energies!
About Hydrogène de France: industrialist and developer of Renewstable® power plants
A specialist in hydrogen technologies, HDF develops, finances, builds and operates multimegawatt industrial power generation infrastructures.
A pioneer in its sector of activity, HDF achieved a world first in 2019 in Martinique, the ClearGen project: the installation and commissioning of a high-powered fuel cell (1 MW), using the hydrogen co-produced by the SARA refinery by transforming it into electricity. This project is funded by Europe (FCH-JU) and SARA.
HDF marketed the Renewstable® power plants, which capture intermittent renewable energy and store it massively in the form of hydrogen to produce stable, 24-hour electricity that can be controlled like a thermal power plant at a competitive price. The first Renewstable® power plant is developed in French Guiana, in collaboration with the French infrastructure fund Meridiam and SARA: the CEOG power plant is the largest in the world storing massively renewable energy via hydrogen, to produce stable and non-polluting electricity day and night for 10,000 households. CEOG will start its construction site in early 2020 and produce its first electrons in early 2022.
As an international player, HDF Energy currently has around ten Renewstable® projects in the advanced development phase in several countries.
- HDF Energy website: www.hdf-energy.com
- HDF Industry website: www.hdf-industry.com
- CEOG Power Plant Website: www.ceog.fr
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191210005394/en/
Contact information
Investor and press relations:
- HDF: communication@hdf-energy.com / +33 (0)5 56 77 77 11 11
Agence 914
Salomé EON :
salome@agence914.fr
+33 6 78 86 66 48
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software27.6.2026 00:28:00 EEST | Press release
VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on
Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 23:30:00 EEST | Press release
Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 21:00:00 EEST | Press release
Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom